Media Releases

Get to know Hematologist-Oncologist Dr. Mohammed Najeeb Al Hallak, who serves patients in Detroit, Michigan.

A skilled hematologist-oncologist, Dr. Al Hallak is affiliated with Gastrointestinal and Neuroendocrine Oncology and the Phase I Clinical-Pharmacology Program at Karmanos Cancer Institute in Detroit, Michigan. He has profound clinical expertise in managing gastrointestinal (GI) malignancies, particularly pancreatic cancer.

Karmanos Cancer Institute specializes in providing cancer care that patients cannot get anywhere else. It is one of just 51 cancer centers throughout the country designated as a comprehensive cancer center by the National Cancer Institute (NCI). This prestigious designation means patients can access treatments exclusive to the center including clinical trials, cancer prevention programs and multidisciplinary teams of cancer specialists.

With a broad educational background, Dr. Al Hallak graduated with his medical degree from the University of Aleppo Faculty of Medicine in Syria. After relocating to the United States, he completed his residency at the University of North Dakota, and his fellowship at the Wayne State University School of Medicine.

Subsequent to his education, the doctor attained board certification in hematology, medical oncology, and internal medicine through the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Among his professional affiliations, he is an active member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Association of Cancer Research.

As for his academic appointment, Dr. Al Hallak serves as a Clinical Assistant Professor within the Department of Oncology at the Wayne State University School of Medicine

An enthusiastic researcher, the goal of his research is to better understand the molecular biology and microenvironment of GI cancers, discover new treatments and prevent treatment-induced toxicities. He is able to translate passion for improving treatment outcomes for GI cancer patients via conducting clinical trials (phase I-III), investigator-initiated and pharma-sponsored.

The doctor works through translational research to identify new biomarkers that help to individualize the treatment choice for patients and provide them with an accurate prediction of the treatment effect as well as a prognosis of their cancer. He is leading the initiative to start a postmortem rapid autopsy program for pancreatic cancer patients in Detroit.

Additionally, Dr. Al Hallak is a co-principal investigator on the Translational Pilot Trial to study the role of different microRNAs in predicting response and resistance to Gemcitabine and Nab-Paclitaxel when used as first-line therapy for metastatic or locally advanced unresectable Pancreatic cancer patients. He is also a co-leader for the Phase II Clinical Trial to study the effect of adding XPO1 inhibitor (Selinexor) to Gemcitabine as a second-line treatment for patients with metastatic or locally advanced unresectable pancreatic cancer patients after non-Gemcitabine regimen failure.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Among his most notable achievements, Dr. Al Hallak has been the recipient of the Awesome Job Award (2016), Outstanding Teacher of the Year Award (2013), and Excellence in Research Award (2011).

Recommended Articles

• How Dogs Are Helping with Lymphoma Research

  According to the Cornell Chronicle (CC), Cornell and Tufts University have received a huge grant for the study of human lymphoma, using a humane approach to test on dogs.The dogs in the study will already have lymphoma and it’s hoped they’ll be cured in the process of this research study.There...

• What Is Kimchi? Health Benefits and Kimchi Recipes

  Kimchi is made up of salted and fermented vegetables, which Koreans enjoy the most. It has been known for about 2,000 years. The most typical Korean dish of steamed rice with kimchi is a popular meal that every Korean loves. According to Korean studies and research, kimchi is a probiotic that has...

• Hope for Recurring Ovarian Cancer Patients

  Ovarian cancer, known as the ‘silent killer’, is the 5th leading cause of cancer-related deaths among women ages 35 to 74. As of this year, it is estimated that more than 22,000 new cases of ovarian cancer will be diagnosed. ...

• What is the Difference Between Alzheimer's Disease and Dementia?

  Dementia is a brain disorder that affects communication and causes difficulty in performing daily tasks. Alzheimer’s disease, on the other hand, affects the parts of the brain that control language, thought, and memory, and it is a specific form of dementia.Though dementia and Alzheimer’s...

• What are the Risk Factors of Jock Itch?

  Fungal infection in the groin area is referred as jock itch. The medical term is known as Tinea cruris. It is caused by a type of fungus called dermatophytes. It grows in the form of a circle on the skin and often looks like a ring. Hence this infection is often known as "ringworm," although no...

• What You Need to Know About Incisional Hernias

  What is a Hernia?A hernia is a medical condition that results from tissue or organs protruding through the abdominal walls. This protrusion is due to a weakness or hole in a muscle. The condition might start without any symptoms, but can lead to serious problems like death if left unattended. Hernia...